2003
Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults
Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, Donaldson C, Parkinson A, Schuchat A, Santosham M, Whitney CG. Effectiveness of the 23-Valent Polysaccharide Vaccine against Invasive Pneumococcal Disease in Navajo Adults. The Journal Of Infectious Diseases 2003, 188: 81-89. PMID: 12825175, DOI: 10.1086/375782.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseOverall vaccine effectivenessNavajo adultsPneumococcal diseaseCase patientsControl patientsPolysaccharide vaccineVaccine effectivenessGeneral United States populationSerious pneumococcal diseasePneumococcal polysaccharide vaccineCohort methodologyUnited States populationCase-control setsActive surveillanceObservational studyMedical conditionsPatientsMedical careDiseaseAdultsDiabetesRegression analysisVaccineAlcoholism
1999
Pneumococcal vaccines: history, current status, and future directions
Butler J, Shapiro E, Carlone G. Pneumococcal vaccines: history, current status, and future directions. The American Journal Of Medicine 1999, 107: 69-76. PMID: 10451012, DOI: 10.1016/s0002-9343(99)00105-9.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccinePolysaccharide vaccinePneumococcal infectionCertain underlying medical conditionsSerious pneumococcal diseaseCommunity-acquired pneumoniaPneumococcal conjugate vaccineUnderlying medical conditionsAnti-pneumococcal antibodiesLarger efficacy trialPrevention of infectionDrug-resistant strainsImmunocompetent childrenPneumococcal diseasePneumococcal vaccineBacterial meningitisConjugate vaccineCase fatalityDNA vaccineInvasive infectionsPneumococcal polysaccharideEfficacy trialsImmune responseMedical conditionsHigh risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply